Fig. 1.
Fig. 1. Study schema. NHL patients were randomized to receive Filgrastim 10 μg/kg/d or Filgrastim and one of four doses of r-metHuSCF (5, 10, 15, or 20 μg/kg/d) for 7 days. All patients were leukapheresed on days 5, 6, and 7 of the collection phase. After a 3- to 10-day rest period, patients received the transplant chemotherapy regimen followed by PBPC infusion and Filgrastim 10 μg/kg/d until ANC ≧5.0 × 109/L for 3 days or 10 × 109/L for 1 day. 1Premedications consisting of diphenhydramine and ranitidine were administered beginning 12 to 24 hours before r-metHuSCF and continuing for at least 48 hours after the last injection. In addition, pseudoephedrine and albuterol were administered 30 to 60 minutes before each injection. 2BM backup to be given if failure to engraft by day 28.

Study schema. NHL patients were randomized to receive Filgrastim 10 μg/kg/d or Filgrastim and one of four doses of r-metHuSCF (5, 10, 15, or 20 μg/kg/d) for 7 days. All patients were leukapheresed on days 5, 6, and 7 of the collection phase. After a 3- to 10-day rest period, patients received the transplant chemotherapy regimen followed by PBPC infusion and Filgrastim 10 μg/kg/d until ANC ≧5.0 × 109/L for 3 days or 10 × 109/L for 1 day. 1Premedications consisting of diphenhydramine and ranitidine were administered beginning 12 to 24 hours before r-metHuSCF and continuing for at least 48 hours after the last injection. In addition, pseudoephedrine and albuterol were administered 30 to 60 minutes before each injection. 2BM backup to be given if failure to engraft by day 28.

Close Modal

or Create an Account

Close Modal
Close Modal